{"date":"2026-07-03","count":16,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6734-2026-07-03-1918-fcslwg","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2026-07-03","time":"19:18:09","subject":"公告本公司115年現金增資延長特定人繳款期限","clause":"第44款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2026-07-03 19:18，「公告本公司115年現金增資延長特定人繳款期限」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7878-2026-07-03-1811-14lrh54","company_id":"7878","company":"藥祇","market":"興櫃","industry":"生技醫療","date":"2026-07-03","time":"18:11:39","subject":"本公司受邀參加兆豐證券舉辦之法人說明會","clause":"第30款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：藥祇（7878），2026-07-03 18:11，「本公司受邀參加兆豐證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4120-2026-07-03-1801-1j46v82","company_id":"4120","company":"友華","market":"上櫃","industry":"生技醫療","date":"2026-07-03","time":"18:01:15","subject":"公告本公司現金股利除息基準日","clause":"第14款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：友華（4120），2026-07-03 18:01，「公告本公司現金股利除息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3716-2026-07-03-1753-9um6xv","company_id":"3716","company":"中化控股","market":"上市","industry":"生技醫療","date":"2026-07-03","time":"17:53:26","subject":"公告本公司第4次買回庫藏股期間屆滿及執行情形","clause":"第35款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：中化控股（3716），2026-07-03 17:53，「公告本公司第4次買回庫藏股期間屆滿及執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3716-2026-07-03-1752-1krv5m7","company_id":"3716","company":"中化控股","market":"上市","industry":"生技醫療","date":"2026-07-03","time":"17:52:03","subject":"代子公司「CHUNGHWA HOLDING CO.,LTD」公告法人董事改派法人代表","clause":"第6款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：中化控股（3716），2026-07-03 17:52，「代子公司「CHUNGHWA HOLDING CO.,LTD」公告法人董事改派法人代表」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4127-2026-07-03-1732-jqp55v","company_id":"4127","company":"天良","market":"上櫃","industry":"生技醫療","date":"2026-07-03","time":"17:32:11","subject":"董事會決議召開115年第二次股東常會相關事宜","clause":"第53款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：天良（4127），2026-07-03 17:32，「董事會決議召開115年第二次股東常會相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4743-2026-07-03-1718-1dts663","company_id":"4743","company":"合一","market":"上櫃","industry":"生技醫療","date":"2026-07-03","time":"17:18:15","subject":"公告本公司內部稽核主管異動事宜","clause":"第8款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：合一（4743），2026-07-03 17:18，「公告本公司內部稽核主管異動事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2026-07-03-1704-4ki9iq","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2026-07-03","time":"17:04:59","subject":"本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之3b期長期追蹤臨床試驗CBL-0303申請，已通過美國FDA IND 30天審查期，將啟動CBL-0303臨床試驗。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2026-07-03 17:04，「本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之3b期長期追蹤臨床試驗CBL-0303申請，已通過美國FDA IND」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6704-2026-07-03-1653-190c74s","company_id":"6704","company":"國璽幹細胞","market":"興櫃","industry":"生技醫療","date":"2026-07-03","time":"16:53:50","subject":"本公司經主管機關核准115年度現金增資調整發行股數及發行總額公告。","clause":"第44款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：國璽幹細胞（6704），2026-07-03 16:53，「本公司經主管機關核准115年度現金增資調整發行股數及發行總額公告。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-07-03-1632-1gyc70x","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-07-03","time":"16:32:28","subject":"公告本公司第二次買回庫藏股執行結果","clause":"第35款","fact_date":"2026-07-05","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-07-03 16:32，「公告本公司第二次買回庫藏股執行結果」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3184-2026-07-03-1551-1whiqjj","company_id":"3184","company":"微邦","market":"興櫃","industry":"生技醫療","date":"2026-07-03","time":"15:51:31","subject":"公告本公司114年度現金股利配發基準日(調整配息率)","clause":"第31款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：微邦（3184），2026-07-03 15:51，「公告本公司114年度現金股利配發基準日(調整配息率)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4114-2026-07-03-1548-7rzr08","company_id":"4114","company":"健喬","market":"上櫃","industry":"生技醫療","date":"2026-07-03","time":"15:48:03","subject":"公告本公司法人董事指派代表人","clause":"第6款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：健喬（4114），2026-07-03 15:48，「公告本公司法人董事指派代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4911-2026-07-03-1529-i4eezk","company_id":"4911","company":"德英","market":"上櫃","industry":"生技醫療","date":"2026-07-03","time":"15:29:53","subject":"公告本公司董事會決議除權息基準日等相關事宜","clause":"第14款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：德英（4911），2026-07-03 15:29，「公告本公司董事會決議除權息基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-07-03-1401-tf28e7","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-07-03","time":"14:01:48","subject":"公告本公司決議現金股利配息基準日","clause":"第14款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-07-03 14:01，「公告本公司決議現金股利配息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7876-2026-07-03-1036-1fqkmsr","company_id":"7876","company":"鼎晉生技","market":"興櫃","industry":"生技醫療","date":"2026-07-03","time":"10:36:57","subject":"澄清媒體報導","clause":"第26款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：鼎晉生技（7876），2026-07-03 10:36，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6446-2026-07-03-0546-smjd50","company_id":"6446","company":"藥華藥","market":"上市","industry":"生技醫療","date":"2026-07-03","time":"05:46:26","subject":"本公司代子公司FORUS Therapeutics Inc.公告新藥BESREMi（Ropeginterferon alfa-2b）獲加拿大衛生部（Health Canada）核准使用於成人真性紅血球增多症（PV）","clause":"第10款","fact_date":"2026-07-02","cite_as":"公開資訊觀測站重大訊息：藥華藥（6446），2026-07-03 05:46，「本公司代子公司FORUS Therapeutics Inc.公告新藥BESREMi（Ropeginterferon al」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}